



Boehringer  
Ingelheim

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, rm. 1061  
Rockville, MD 20850

2200 '99 MAY -3 A9:45

Boehringer Ingelheim  
Pharmaceuticals, Inc.

**Ref: Docket No. 99D-0236**  
**Draft Guidance for Industry:**  
**Skin Irritation and Sensitization Testing of**  
**Generic Transdermal Drug Products**

April 30, 1999

Dear Sir/Madam:

Boehringer Ingelheim Pharmaceuticals, Inc. has reviewed the FDA draft guidance on "Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products", and is taking this opportunity to provide comments on the guidance.

Kathryn M. Jason, Ph.D  
Telephone (203) 798-4352  
Telefax (203) 791-6262  
E-Mail [kjason@rdg.boehringer-ingelheim](mailto:kjason@rdg.boehringer-ingelheim)

900 Ridgebury Rd/P.O. Box 368  
Ridgefield, CT 06877-0368  
Telephone (203) 798-9988

We applaud the Agency's efforts in developing a guidance to assist sponsors of transdermal drug abbreviated new drug applications. The draft guidance clearly lays out the current regulatory thinking for evaluating the skin irritation and sensitization potential of generic transdermal systems. While we believe that the document has been carefully developed and that most of the recommendations are appropriate, we as an ethical pharmaceutical company that has developed and marketed a transdermal product for the past 15 years, offer the following comments for your consideration.

The guidance should give some recommendations for the choice of the subjects. Experience in marketing a once-a-week system for the past 13 years has been that women of Northern European lineage are more susceptible to skin irritation and sensitization than other female ethnic groups and males. In the Cumulative Skin Irritation Study we recommend that a substantial number of the study participants (one third or greater) be women of Northern European lineage to obtain statistical power in the study.

Secondly, we recommend that either the lowest dose possible of the active drug substance be used in the two study designs if normal volunteers are recruited or that the dose be titrated to the proper therapeutic level if patients are recruited. While it is important that potential skin irritation and sensitization be studied

99D-0236

C6

with both drug and excipients together in these study designs, care should be taken to ensure the safety of the subjects.

We commend the Agency for its efforts to develop this guidance and would welcome the opportunity to further discuss the Agency issues pertaining to skin irritation and sensitization following transdermal drug delivery in general or to our comments in general.

Sincerely,



Kathryn M. Jason, Ph.D  
Sr. Associate Director,  
Drug Regulatory Affairs

**FedEx** USA AirbillFedEx  
Tracking  
Number

803239299979

Form  
I.D. No.

0200

SPH41

Recipient's Copy

**1 From**  
Date **4/30/1999**Sender's Name **Dr. Kathryn Jason** Phone **(203) 798-4352**Company **BOEHRINGER INGELHEIM PHARM**Address **900 RIDGEBURY RD**City **RIDGEFIELD** State **CT** ZIP **06877****2 Your Internal Billing Reference Information****3 To**  
Recipient's Name **Dockers Management Branch** Phone ( )Company **Food and Drug Administration**Address **5630 Fishers Lane, Rm. 1061**City **Rockville,** State **MD** ZIP **20850**

For HOLD at FedEx Location check here

Hold Weekday

(Not available with

FedEx First Overnight)

Hold Saturday

(Available for FedEx Priority Overnight


and FedEx 2Day only)

For Saturday Delivery check here

(Extra Charge. Not available to all locations)

(Available for FedEx Priority Overnight

and FedEx 2Day only)



8 0 3 2 3 9 2 9 9 7 9

**4a Express Package Service Packages under 150 lbs.** Delivery commitment may be later in some areas.☒ FedEx Priority Overnight (Next business morning)  
☐ FedEx Standard Overnight (Next business afternoon)  
☐ FedEx First Overnight (Earliest next business morning delivery to select locations) (Higher rates apply)  
☐ FedEx 2Day (Second business day)  
☐ FedEx Express Saver (Third business day)  
FedEx Letter Rate not available. Minimum charge: One pound rate.**4b Express Freight Service Packages over 150 lbs.** Delivery commitment may be later in some areas.☐ FedEx Overnight Freight (Next business day)  
☐ FedEx 2Day Freight (Second business day)  
☐ FedEx Express Saver Freight (Up to 3 business days)

(Call for delivery schedule. See back for detailed descriptions of freight services.)

**5 Packaging**  
☒ FedEx Letter (Declared value limit \$500)  
☐ FedEx Pak  
☐ FedEx Box  
☐ FedEx Tube  
☐ Other Pkg.**6 Special Handling** (One box must be checked) (Shipper's Declaration not required)Does this shipment contain dangerous goods? ☒ No ☐ Yes☐ Dry Ice ☐ CA Cargo Aircraft Only

Dry Ice, 9, UN 1845 x kg. \*Dangerous Goods cannot be shipped in FedEx packaging.

**7 Payment** Obtain Recipient FedEx Account No.Bill to: ☒ Sender (Account no. in section 1 will be billed) ☐ Recipient ☐ Third Party ☐ Credit Card ☐ Cash/Check

(Enter FedEx account no. or Credit Card no. below)



Total Packages Total Weight Total Declared Value\* Total Charges

\$ .00 \$

\*When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information.

Credit Card Auth.

**8 Release Signature**

Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

Questions?

Call 1-800-Go-FedEx (800)463-3339

288

WCSL 1197  
Rev. Date 8/97  
Part #151557  
©1994-97 FedEx  
PRINTED IN U.S.A.

004250891 7